Comparison of the Activities of the Lantibiotics Nisin and Lacticin 3147 Against Clinically Significant Mycobacteria
Overview
Pharmacology
Authors
Affiliations
The aim of this study was to use the microtitre alamarBlue assay to investigate and compare the antimycobacterial potential of the lantibiotics nisin and lacticin 3147 against a representative cohort of clinically significant mycobacteria, i.e. Mycobacterium tuberculosis H37Ra, Mycobacterium avium subsp. paratuberculosis (MAP) ATCC 19698 and Mycobacterium kansasii CIT11/06. Lacticin 3147 displayed potent activity against all strains of mycobacteria, with MIC(90) values (lowest concentration of lantibiotic that prevented growth of >90% of the bacterial population) of 60 mg/L and 15 mg/L for M. kansasii and MAP, respectively. Lacticin 3147 was particularly effective against M. tuberculosis H37Ra, with a MIC(90) value of 7.5mg/L. Nisin, although inhibitory, was generally less potent against all strains of mycobacteria, with MIC(90) values of 60 mg/L for M. kansasii and >60 mg/L for MAP and M. tuberculosis H37Ra. Thus, lacticin 3147 is a potent antimycobacterial peptide that shows superior activity compared with nisin at physiological pH.
A Comprehensive Review on Bioactive Molecules and Advanced Microorganism Management Technologies.
Wali A, Talath S, Sridhar S, Shareef J, Goud M, Rangraze I Curr Issues Mol Biol. 2024; 46(11):13223-13251.
PMID: 39590383 PMC: 11592628. DOI: 10.3390/cimb46110789.
Bacteriocins: potentials and prospects in health and agrifood systems.
Reuben R, Torres C Arch Microbiol. 2024; 206(5):233.
PMID: 38662051 PMC: 11045635. DOI: 10.1007/s00203-024-03948-y.
Host microbiome in tuberculosis: disease, treatment, and immunity perspectives.
Pant A, Das B, Arimbasseri G Front Microbiol. 2023; 14:1236348.
PMID: 37808315 PMC: 10559974. DOI: 10.3389/fmicb.2023.1236348.
Shleeva M, Kondratieva D, Kaprelyants A Pharmaceutics. 2023; 15(7).
PMID: 37514078 PMC: 10383908. DOI: 10.3390/pharmaceutics15071893.
cell-wall and antimicrobial peptides: a mission impossible?.
Jacobo-Delgado Y, Rodriguez-Carlos A, Serrano C, Rivas-Santiago B Front Immunol. 2023; 14:1194923.
PMID: 37266428 PMC: 10230078. DOI: 10.3389/fimmu.2023.1194923.